Therapy News and Research

RSS

Rehabilitation helps restore erectile function post radical prostatectomy

Results from a study published in BJU International indicate that penile rehabilitation programs can help restore erectile function following nerve-sparing robot-assisted radical prostatectomy.

10 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

New assay test shows positive results for patients with recurrent or metastatic breast cancer

When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

Surgical patients with chronic psychological symptoms require psychotherapeutic treatment

In their study, the research group, headed by Privatdozent Dr. Henning Krampe, psychologist at the Charité Department of Anesthesiology and Intensive Care Medicine, Prof. Claudia Spies, Director of the Charité Department of Anesthesiology and Intensive Care Medicine and Prof. Elmar Brähler, Head of the Department of Medical Psychology and Medical Sociology at the University of Leipzig, initially recorded how many patients faced by a forthcoming operation were interested in psychotherapy sessions and to what extent this interest was associated with the increased psychological distress occurring before the operation. Finally, the scientists examined whether changes in the psychological symptoms took place during the six months following the surgery.

10 Dec 2012

Physician's Technology launches WilloMD iLaserX device

The Italian Renaissance sculptor Michelangelo once declared "everything hurts". Baby boomers are more active than ever and stress their joints. Millions rely on dangerous pain meds and injections to stay active. Pain medication and injections can be dangerous and even lethal. Popular therapeutic pain laser technology offers hope but is not practical for home use and is out of reach of a vast patient population.

10 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

MSKCC establishes new pancreatic cancer research center

A new pancreatic cancer research center has been created at Memorial Sloan-Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.

10 Dec 2012

Genzyme receives EC approval for Thyrogen product label expansion

Genzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen (thyrotropin alfa) with a wider irradiation dose range for postoperative thyroid remnant ablation.

10 Dec 2012

BlueGenics aims to discover new drugs from deep sea to combat osteoporosis

Searching for substances from the deep sea to combat osteoporosis and other human common diseases is one of the objectives of the new European research project "BlueGenics" which has received funding of EUR 6 million from the European Commission.

10 Dec 2012

Mesupron could extend progression-free survival for metastatic breast cancer patients

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron- is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system.

10 Dec 2012

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

10 Dec 2012

IDSA guidelines describe best methods for diagnosis of prosthetic joint infections

Of the one million people each year who get hips and knees replaced, as many as 20,000 will get an infection in the new joint, a number that is expected to skyrocket in the next 20 years. Multispecialty physician teams need to work together to reduce disability, death and costs associated with the ever-growing number of these prosthetic joint infections, note the first guidelines on the topic being released by the Infectious Diseases Society of America (IDSA).

9 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Anti-seizure drug benefits women with severe morning sickness

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

8 Dec 2012

IQWiG investigates benefits of rilpivirine for HIV treatment

Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).

8 Dec 2012

Therapy News and Research

Rehabilitation helps restore erectile function post radical prostatectomy

RET fusion signals unique NSCLC subtype

New assay test shows positive results for patients with recurrent or metastatic breast cancer

New hope for leukemia patients

Surgical patients with chronic psychological symptoms require psychotherapeutic treatment

Physician's Technology launches WilloMD iLaserX device

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Ibrutinib may effectively combat chronic lymphocytic leukemia

MSKCC establishes new pancreatic cancer research center

Genzyme receives EC approval for Thyrogen product label expansion

BlueGenics aims to discover new drugs from deep sea to combat osteoporosis

Mesupron could extend progression-free survival for metastatic breast cancer patients

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

IDSA guidelines describe best methods for diagnosis of prosthetic joint infections

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Anti-seizure drug benefits women with severe morning sickness

IQWiG investigates benefits of rilpivirine for HIV treatment

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News